Get the Stockscreener App
9.44
1.56%
-0.15
Immatics N V stock is traded at $9.44, with a volume of 350.52K.
It is down -1.56% in the last 24 hours and up +0.96% over the past month.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
See More
Previous Close:
$9.59
Open:
$9.68
24h Volume:
350.52K
Relative Volume:
0.78
Market Cap:
$1.29B
Revenue:
$43.34M
Net Income/Loss:
$-247.99M
P/E Ratio:
-4.7827
EPS:
-1.9738
Net Cash Flow:
$-224.28M
1W Performance:
-2.18%
1M Performance:
+0.96%
6M Performance:
-4.07%
1Y Performance:
+60.00%
1-Day Range:
$9.39
$9.68
1-Week Range:
$9.39
$9.98
52-Week Range:
$5.05
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
9.44 | 1.33B | 43.34M | -247.99M | -224.28M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| May-28-25 | Initiated | Deutsche Bank | Buy |
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics (IMTX): Baker Bros. group reports 9.5M-share, 7% ownership stake - Stock Titan
Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Immatics N.V. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Immatics N.V. (IMTX) Stock Analysis: Unveiling An 89.67% Potential Upside For Investors - directorstalkinterviews.com
How Immatics N.v. (IMTX) Affects Rotational Strategy Timing - Stock Traders Daily
Immatics (IMTX): Will Anzu-cel Take The PRAME Crown In Advanced Melanoma? - RTTNews
Immatics (IMTX) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Immatics N.V. (IMTX) Stock Analysis: Exploring a 105% Upside Potential in the Biotech Sector - directorstalkinterviews.com
IMTX|Immatics NV|Price:8.660|Chg%:-0.540 - TradingKey
Immatics Q1 2026 Earnings: EPS Misses Estimates as Pipeline Advances Offset Financial HeadwindsCapex Guidance - dars.gov.et
Immatics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Immatics (IMTX) general counsel Pepin Nelson reports insider status - Stock Titan
Immatics NV (IMTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immatics N.V. (NASDAQ:IMTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immatics Market Sentiment - Benzinga
Immatics NV (IMTX) Cash Flow - TradingKey
Immatics N.V. Revenue Breakdown – NASDAQ:IMTX - TradingView
IMTX|Immatics NV|Price:9.080|Chg%:-0.210 - TradingKey
Immatics NV (IMTX) Income Statement - TradingKey
Immatics N.V. (IMTX) Stock Analysis: A Deep Dive Into Its 103% Potential Upside - DirectorsTalk Interviews
Immatics NV (IMTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immatics NV : Leerink Partners Assumes Covera - Moomoo
Immatics stock trades steady as pipeline and cash position frame biotech outlook - Ad-hoc-news.de
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflected in Wider Loss, Yet Stock Rises on Pipeline ProgressInterim Report - dars.gov.et
Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026 - Bitget
Immatics N.V. (IMTX) Stock: Cancer Treatment Pipeline Gains Momentum With Cell Therapy and Bispecific Programs - parameter.io
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - Investing News Network
MRNA Advances Cancer Pipeline With New Immunotherapy Study - TradingView
Immatics Announces Three ESMO 2026 Presentations Highlighting PRAME Cell Therapy and Bispecific Pipeline - Quiver Quantitative
Immatics’ three ESMO presentations span melanoma and solid tumors - Stock Titan
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage R&D InvestmentEarnings Growth Analysis - dars.gov.et
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Amid Continued Pipeline ProgressPre-Announcement Alert - dars.gov.et
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Advances Pipeline - dars.gov.et
(IMTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immatics (IMTX) Dips 2.8% as Biotech Stock Tests Key Support Near $9.20Buffered ETF - dars.gov.et
Immatics (IMTX) Slides 3.11% Amid Biotech Sector Pressure – Support at $9.17 in FocusRounding Bottom - dars.gov.et
Immatics (IMTX) Holds Near Support as Slight Dip Signals Cautious TradingGap Down Bounce Plays - dars.gov.et
Immatics stock holds attention. The focus shifts to its pipeline. - Ad Hoc News
Immatics (IMTX) Q1 2026 Earnings: EPS Miss Weighs on Pre-Revenue Biotech StockRevenue Beat Analysis - Bölüm Sonu Canavarı
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates as Development Costs WeighQuarterly Earnings - dars.gov.et
Immatics N.V. Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage InvestmentEarnings Sentiment Score - dars.gov.et
Responsive Playbooks and the IMTX Inflection - Stock Traders Daily
Immatics N.V. (IMTX) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Costs RiseEBITDA Estimate Trend - dars.gov.et
Immatics N.V. Actuals & Estimates (NASDAQ:IMTX) - TradingView
Immatics (IMTX) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D InvestmentRevenue Guidance Range - dars.gov.et
Enterprise value to revenue forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Price to book forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Enterprise value to EBIT forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Enterprise value to EBIT forward of Immatics N.V. – MUN:4A3 - TradingView
IMTX Forecast — Price Target — Prediction for 2027 - TradingView
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):